Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Carmine Stengone — FY2025 total compensation $3,409,448

Carmine Stengone is President and Chief Executive Officer of Contineum Therapeutics, Inc. (CTNM). The company reported total compensation of $3,409,448 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$655,620
Bonus$0
Stock awards$0
Option awards$2,291,640
Non-equity incentive plan$450,739
Pension and non-qualified deferred compensation$0
All other compensation$11,449
Total$3,409,448

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Contineum Therapeutics, Inc. filed April 30, 2026, accession 0001628280-26-028881.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025President and Chief Executive Officer$655,620$0$0$2,291,640$450,739$0$11,449$3,409,448
FY2024President and Chief Executive Officer$608,120$55,000$0$3,806,147$418,146$0$12,627$4,900,039

Totals as disclosed in each year's own compensation disclosure for Contineum Therapeutics, Inc..

04

The other named executive officers of Contineum Therapeutics, Inc.

Named executive officerRoleFY2025 total
Carmine Stengone this pagePresident and Chief Executive Officer$3,409,448
Timothy WatkinsChief Medical Officer and Head of Development$1,763,323
Peter SloverChief Financial Officer$1,577,903

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Contineum Therapeutics, Inc. compensation brief.

05

The company page

Carmine Stengone's compensation sits inside Contineum Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Contineum Therapeutics, Inc. (CTNM) compensation brief